These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16081686)

  • 21. In vitro antineoplastic effects of auranofin in canine lymphoma cells.
    Zhang H; Rose BJ; Pyuen AA; Thamm DH
    BMC Cancer; 2018 May; 18(1):522. PubMed ID: 29724201
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New insights into redox homeostasis as a therapeutic target in B-cell malignancies.
    Graczyk-Jarzynka A; Zagozdzon R; Muchowicz A; Siernicka M; Juszczynski P; Firczuk M
    Curr Opin Hematol; 2017 Jul; 24(4):393-401. PubMed ID: 28402987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Activating transcription factor 3 is crucial for antitumor activity and to strengthen the antiviral properties of Onconase.
    Vert A; Castro J; Ribó M; Benito A; Vilanova M
    Oncotarget; 2017 Feb; 8(7):11692-11707. PubMed ID: 28035074
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dimeric peroxiredoxins are druggable targets in human Burkitt lymphoma.
    Trzeciecka A; Klossowski S; Bajor M; Zagozdzon R; Gaj P; Muchowicz A; Malinowska A; Czerwoniec A; Barankiewicz J; Domagala A; Chlebowska J; Prochorec-Sobieszek M; Winiarska M; Ostaszewski R; Gwizdalska I; Golab J; Nowis D; Firczuk M
    Oncotarget; 2016 Jan; 7(2):1717-31. PubMed ID: 26636537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitochondria and redox homoeostasis as chemotherapeutic targets.
    Briehl MM; Tome ME; Wilkinson ST; Jaramillo MC; Lee K
    Biochem Soc Trans; 2014 Aug; 42(4):939-44. PubMed ID: 25109983
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
    Barr PM; Miller TP; Friedberg JW; Peterson DR; Baran AM; Herr M; Spier CM; Cui H; Roe DJ; Persky DO; Casulo C; Littleton J; Schwartz M; Puvvada S; Landowski TH; Rimsza LM; Dorr RT; Fisher RI; Bernstein SH; Briehl MM
    Blood; 2014 Aug; 124(8):1259-65. PubMed ID: 25016003
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer.
    Morrison JA; Pike LA; Sams SB; Sharma V; Zhou Q; Severson JJ; Tan AC; Wood WM; Haugen BR
    Mol Cancer; 2014 Mar; 13():62. PubMed ID: 24645981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma.
    Gustafson HL; Yao S; Goldman BH; Lee K; Spier CM; LeBlanc ML; Rimsza LM; Cerhan JR; Habermann TM; Link BK; Maurer MJ; Slager SL; Persky DO; Miller TP; Fisher RI; Ambrosone CB; Briehl MM
    Am J Hematol; 2014 Jun; 89(6):639-45. PubMed ID: 24633940
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Annotation enrichment analysis: an alternative method for evaluating the functional properties of gene sets.
    Glass K; Girvan M
    Sci Rep; 2014 Feb; 4():4191. PubMed ID: 24569707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma.
    Phipps-Yonas H; Cui H; Sebastiao N; Brunhoeber PS; Haddock E; Deymier MJ; Klapper W; Lybarger L; Roe DJ; Hastings KT
    Front Immunol; 2013; 4():425. PubMed ID: 24409177
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress and redox state-regulating enzymes have prognostic relevance in diffuse large B-cell lymphoma.
    Peroja P; Pasanen AK; Haapasaari KM; Jantunen E; Soini Y; Turpeenniemi-Hujanen T; Bloigu R; Lilja L; Kuittinen O; Karihtala P
    Exp Hematol Oncol; 2012 Mar; 1(1):2. PubMed ID: 23210982
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Size matters: sequential mutations in tumorigenesis may reflect the stochastic effect of mutagen target sizes.
    Long K; Abuelenen T; Pava L; Bastille M; Blanck G
    Genes Cancer; 2011 Oct; 2(10):927-31. PubMed ID: 22701759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thioredoxin and thioredoxin target proteins: from molecular mechanisms to functional significance.
    Lee S; Kim SM; Lee RT
    Antioxid Redox Signal; 2013 Apr; 18(10):1165-207. PubMed ID: 22607099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma.
    Li C; Thompson MA; Tamayo AT; Zuo Z; Lee J; Vega F; Ford RJ; Pham LV
    Oncotarget; 2012 Mar; 3(3):314-26. PubMed ID: 22447839
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thioredoxin binding protein (TBP)-2/Txnip and α-arrestin proteins in cancer and diabetes mellitus.
    Masutani H; Yoshihara E; Masaki S; Chen Z; Yodoi J
    J Clin Biochem Nutr; 2012 Jan; 50(1):23-34. PubMed ID: 22247597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Manipulation of cellular redox parameters for improving therapeutic responses in B-cell lymphoma and multiple myeloma.
    Goel A; Spitz DR; Weiner GJ
    J Cell Biochem; 2012 Feb; 113(2):419-25. PubMed ID: 21956712
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A strategy for full interrogation of prognostic gene expression patterns: exploring the biology of diffuse large B cell lymphoma.
    Rimsza LM; Unger JM; Tome ME; Leblanc ML
    PLoS One; 2011; 6(8):e22267. PubMed ID: 21829609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The rate of oxygen utilization by cells.
    Wagner BA; Venkataraman S; Buettner GR
    Free Radic Biol Med; 2011 Aug; 51(3):700-12. PubMed ID: 21664270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Accurate classification of diffuse large B-cell lymphoma into germinal center and activated B-cell subtypes using a nuclease protection assay on formalin-fixed, paraffin-embedded tissues.
    Rimsza LM; Wright G; Schwartz M; Chan WC; Jaffe ES; Gascoyne RD; Campo E; Rosenwald A; Ott G; Cook JR; Tubbs RR; Braziel RM; Delabie J; Miller TP; Staudt LM
    Clin Cancer Res; 2011 Jun; 17(11):3727-32. PubMed ID: 21364035
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increased cytochrome c correlates with poor survival in aggressive lymphoma.
    Wilkinson ST; Johnson DB; Tardif HL; Tome ME; Briehl MM
    Oncol Lett; 2010 Mar; 1(2):227-230. PubMed ID: 20798784
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.